Nivolumab Plus Ipilimumab In Patients With Advanced Non-Clear Cell Renal Cell Carcinoma (Nccrcc): Safety And Efficacy From Checkmate 920.

Scott S. Tykodi,Lucio N. Gordan,Robert S. Alter,Edward Arrowsmith,Michael Roger Harrison,Ivor John Percent,Rakesh Singal,Peter J. Van Veldhuizen,Daniel J. George,Thomas E. Hutson,Joshua Zhang,Jesus Zoco,Jennifer L. Johansen,Arash Rezazadeh Kalebasty

JOURNAL OF CLINICAL ONCOLOGY（2021）

引用 18|浏览3

暂无评分

摘要

309Background: The long-term efficacy and tolerability of nivolumab (NIVO) 3 mg/kg + ipilimumab (IPI) 1 mg/kg Q3W × 4 doses followed by NIVO 3 mg/kg Q2W for previously untreated advanced RCC (aRCC)...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要